Colon and Rectal

The CDC developed the Colorectal Cancer Control Program (CRCCP) to provide direct colorectal cancer (CRC) screening services to low-income, uninsured, or underinsured populations known to have low CRC screening rates. However, early evaluators found the program was insufficient to detect impact at the state level. In response to those findings, the CDC redesigned CRCCP and funded a new 5-year grant period beginning in 2015. How did the program fare this time? CDC researchers say it “shows promise.”

The CRCCP funds 23 states, 6 universities, and 1 tribal organization to partner with health care systems, implementing evidence-based interventions (EBIs). In this study, the researchers analyzed data reported by 387 of 413 clinics of varying sizes, representing 3,438 providers, and serving a screening-eligible population of 722,925 patients.

The researchers say their evaluation suggests that the CRCCP is working as intended: Program reach was measurable and “substantial,” clinics enhanced EBIs in place or implemented new ones, and the overall average screening rate rose.

At baseline, the screening rate was low (43%), and lowest in rural clinics—although evidence indicates that death rates for CRC are highest among people living in rural areas. In the first year, the overall screening rate increased by 4.4 percentage points. Still, that 47.3% is “much lower” than the commonly cited 67.3% from the 2016 Behavioral Risk Factor Surveillance System, the researchers note. They add, though, that the results confirm that grantees are working with clinics serving the intended populations and indicate the significant gap in CRC screening rates between those reached by the CRCCP and the US population overall.

Many clinics had ≥ 1 EBI or supporting activity (SA) already in place. Grantees used CRCCP resources to implement new or to enhance EBIs in 95% of the clinics, most often patient reminder activities and provider assessment and feedback. Most of the clinics used CRCCP resources for SAs, such as small media and provider education. Only 12% of clinics used resources for supporting community health workers. However, nearly half the clinics conducted planning activities for future implementation of community health workers and patient navigators.

Nearly 80% of the clinics reported having a CRC screening champion, 73% had a CRC screening policy, and 50% had either 3 or 4 EBIs in place at the end of the first year—all factors that the researchers suggest may support greater screening rate increases.

The CDC developed the Colorectal Cancer Control Program (CRCCP) to provide direct colorectal cancer (CRC) screening services to low-income, uninsured, or underinsured populations known to have low CRC screening rates. However, early evaluators found the program was insufficient to detect impact at the state level. In response to those findings, the CDC redesigned CRCCP and funded a new 5-year grant period beginning in 2015. How did the program fare this time? CDC researchers say it “shows promise.”

The CRCCP funds 23 states, 6 universities, and 1 tribal organization to partner with health care systems, implementing evidence-based interventions (EBIs). In this study, the researchers analyzed data reported by 387 of 413 clinics of varying sizes, representing 3,438 providers, and serving a screening-eligible population of 722,925 patients.

The researchers say their evaluation suggests that the CRCCP is working as intended: Program reach was measurable and “substantial,” clinics enhanced EBIs in place or implemented new ones, and the overall average screening rate rose.

At baseline, the screening rate was low (43%), and lowest in rural clinics—although evidence indicates that death rates for CRC are highest among people living in rural areas. In the first year, the overall screening rate increased by 4.4 percentage points. Still, that 47.3% is “much lower” than the commonly cited 67.3% from the 2016 Behavioral Risk Factor Surveillance System, the researchers note. They add, though, that the results confirm that grantees are working with clinics serving the intended populations and indicate the significant gap in CRC screening rates between those reached by the CRCCP and the US population overall.

Many clinics had ≥ 1 EBI or supporting activity (SA) already in place. Grantees used CRCCP resources to implement new or to enhance EBIs in 95% of the clinics, most often patient reminder activities and provider assessment and feedback. Most of the clinics used CRCCP resources for SAs, such as small media and provider education. Only 12% of clinics used resources for supporting community health workers. However, nearly half the clinics conducted planning activities for future implementation of community health workers and patient navigators.

Nearly 80% of the clinics reported having a CRC screening champion, 73% had a CRC screening policy, and 50% had either 3 or 4 EBIs in place at the end of the first year—all factors that the researchers suggest may support greater screening rate increases.

The CDC developed the Colorectal Cancer Control Program (CRCCP) to provide direct colorectal cancer (CRC) screening services to low-income, uninsured, or underinsured populations known to have low CRC screening rates. However, early evaluators found the program was insufficient to detect impact at the state level. In response to those findings, the CDC redesigned CRCCP and funded a new 5-year grant period beginning in 2015. How did the program fare this time? CDC researchers say it “shows promise.”

The CRCCP funds 23 states, 6 universities, and 1 tribal organization to partner with health care systems, implementing evidence-based interventions (EBIs). In this study, the researchers analyzed data reported by 387 of 413 clinics of varying sizes, representing 3,438 providers, and serving a screening-eligible population of 722,925 patients.

The researchers say their evaluation suggests that the CRCCP is working as intended: Program reach was measurable and “substantial,” clinics enhanced EBIs in place or implemented new ones, and the overall average screening rate rose.

At baseline, the screening rate was low (43%), and lowest in rural clinics—although evidence indicates that death rates for CRC are highest among people living in rural areas. In the first year, the overall screening rate increased by 4.4 percentage points. Still, that 47.3% is “much lower” than the commonly cited 67.3% from the 2016 Behavioral Risk Factor Surveillance System, the researchers note. They add, though, that the results confirm that grantees are working with clinics serving the intended populations and indicate the significant gap in CRC screening rates between those reached by the CRCCP and the US population overall.

Many clinics had ≥ 1 EBI or supporting activity (SA) already in place. Grantees used CRCCP resources to implement new or to enhance EBIs in 95% of the clinics, most often patient reminder activities and provider assessment and feedback. Most of the clinics used CRCCP resources for SAs, such as small media and provider education. Only 12% of clinics used resources for supporting community health workers. However, nearly half the clinics conducted planning activities for future implementation of community health workers and patient navigators.

Nearly 80% of the clinics reported having a CRC screening champion, 73% had a CRC screening policy, and 50% had either 3 or 4 EBIs in place at the end of the first year—all factors that the researchers suggest may support greater screening rate increases.

Access to specialized services has been a consistently complex problem for many integrated health care systems, including the Veterans Health Administration (VHA). About two-thirds of veterans experience significant barriers when trying to obtain medical care.¹ While these problems partly mirror difficulties that nonveterans face as well, there is a unique obligation toward those who put life and health at risk during their military service.²

To better meet demands, the VHA expanded personnel and clinic infrastructure with more providers and a network of community-based outpatient clinics (CBOC) that created more openings for clinic visits.³ Yet regional variability remains a significant problem for primary and even more so for specialty medical services.

Recent data show that more than one-fifth of all veterans live in areas with low population density and shortages of health care providers.⁴ The data point at a special problem in this context because these veterans often face long travel times to centers offering specialty services. The introduction of electronic consults functions as an alternative venue to obtain expert input but amounts to only 2% of total consult volume.⁵ A more interactive approach with face-to-face teleconferencing, case discussions, and special training led by expert clinicians has further improved access in such underserved areas and played a key role in the success of the VHA hepatitis C treatment initiative.⁶

Despite its clearly proven role and success, these e-consults come with some conceptual shortcomings. A key caveat is the lack of direct patient involvement. Obtaining information from the source rather than relying on symptoms documented by a third person can be essential in approaching medical problems. Experts may be able to tease out the often essential details of a history when making a diagnosis. A direct contact adds an additional, perhaps less tangible, component to the interaction that relies on verbal and nonverbal components of personal interactions and plays an important role in treatment success. Prior studies strongly link credibility of and trust in a provider as well as the related treatment success to such aspects of communication.^7,8

Gastroenterology Telemedicine Services

The George E. Wahlen VA Medical Center in Salt Lake City, Utah, draws from a large catchment area that extends from the southern border of Utah to the neighboring states of Idaho, Wyoming, Nevada, and Montana. Large stretches of this territory are remote with population densities well below 5 persons per square mile. The authors therefore devised a specialty outreach program relying on telemedicine for patients with gastrointestinal and liver diseases and present the initial experience with the implementation of this program.

Phase 1: Finding the Champions

Prior studies clearly emphasized that most successful telemedicine clinics relied on key persons (“champions”) promoting the idea and carrying the additional logistic and time issues required to start and maintain the new program^.9,10 Thus we created a small team that defined and refined goals, identified target groups, and worked out the logistics. Based on prior experiences, we focused initially on veterans with more chronic and likely functional disorders, such as diarrhea, constipation, dyspepsia, or nausea. The team also planned to accept patients with chronic liver disorders or abnormal test results that required further clarification. By consensus, the group excluded acute problems and bleeding as well as disorders with pain as primary manifestations. The underlying assumption was that a direct physical examination was less critical in most of these cases.

Phase 2: Outreach

Clinic managers and medical directors of the affiliated CBOC were informed of the planned telemedicine clinic. Also, we identified local champions who could function as point persons and assist in the organization of visits. One member of the team personally visited key sites to discuss needs and opportunities with CBOC personnel during a routine staff meeting. The goal was to introduce the program, the key personnel, to explain criteria for appropriate candidates that may benefit from telemedicine consults, and to agree on a referral pathway. Finally, we emphasized that the consultant would always defer to the referring provider or patient and honor their requests.

Phase 3: Identifying Appropriate Patients

The team planned for and has since used 4 different pathways to identify possible candidates for telemedicine visits. The consult triaging process with telemedicine is an option that is brought up with patients if their travel to the facility exceeds 100 miles. Similarly, the team reviews procedural requests to optimize diagnostic yields and limit patient burden. For example, if endoscopic testing is requested to address chronic abdominal pain or other concerns that had already prompted a similar request with negative results, then the team will ask for feedback and recommend a telemedicine consultation prior to performing the procedure. Telemedicine also is offered for follow-up encounters to veterans seen in the facility for clinical or procedural evaluations if they live ≥ 40 miles away. The 2 other pathways are requests from referring providers or patients that specifically ask for telemedicine visits.

Phase 4: Implementation

Since rolling out the program in November 2016, video visits have been used for more than 150 clinic encounters. Within the first 12 months, 124 patients were seen at least once using telemedicine links. Of 144 visits, 54 (38%) were follow-up visits; the rest constituted initial consultations. Focusing on initial encounters only, veterans specifically asked for a telemedicine visit in 16 cases (17.8%). One-third of these referrals was specifically marked as a telemedicine visit by the primary care provider. In the remaining cases, the triaging personnel brought up the possibility of a telemedicine interaction and requested feedback from the referring provider.

Veterans resided in many different areas within and outside of the facility’s immediate referral area (Figure). 

Beyond obtaining contextual data and information about the specific clinical manifestations, the rationale for these encounters was a detailed discussion of the problem and treatment options available. Ablative therapy in Barrett esophagus best exemplifies the potential relevance of such an encounter: Although conceptually appealing to decrease cancer risk, the approach requires a significant commitment typically involving repeated sessions of radiofrequency ablation followed by intense endoscopic surveillance. With travel distances of several hundred miles in these cases, these encounters provide relevant information to patients and the opportunity to make informed decisions without the burden and cost of a long trip.

A shift in telemedicine encounters will likely occur that will increasingly rely on access from home computers or handheld devices. However, the initial phase of this program relied on connections through a CBOC. Coordination between 2 sites adds a level of complexity to ensure availability of space and videoconferencing equipment. To limit the logistic burden and improve cost-effectiveness, the authors did not expect or request the presence of the primary or another independent provider. Instead, the team communicated with a locally designated point person who coordinated the remote encounters and assisted in implementing some of the suggested next steps. Prior site visits and communications with referring providers had established channels of communication to define concerns or highlight findings. The same channels also allowed the team to direct its attention to specific aspects of the physical examination to support or rule out a presumptive diagnosis.

If additional testing was suggested, Telemedicine Services generally ordered the appropriate assessments unless veterans requested relying on local resources better known to personnel at the remote site. The most common diagnostic steps recommended were laboratory tests (n = 21; 14.6%), endoscopic procedures (n = 18; 12.5%), and radiologic studies (n = 17; 11.8%) (Table 2).

Discussion

The initial implementation of a specialty telemedicine clinic taught us several lessons that will not only guide this program expansion, but also may be relevant for others introducing telemedicine into their specialty clinics. At first glance, videoconferencing with patients resembles more conventional clinic encounters. However, it adds another angle as many steps from scheduling a visit to implementing recommendations rely on different members at the remote site. Thus, the success of such a program depends on establishing a true partnership with the teams at the various satellite sites. It also requires ongoing feedback from all team members and fine-tuning to effectively integrate it into the routine operations of both sites.

Feedback about the program has been very positive with comments often asking for an expansion beyond gastroenterology. Concerns largely were limited to scheduling problems that may become less relevant if the new telehealth initiative moves forward and enables health care providers to directly connect with computers or handheld devices at the patient’s home. Prior studies demonstrated that most individuals have access to such technology and accept it as a viable or even attractive option for medical encounters.^11,12

For some, remaining in the comfort of their own home is not only more convenient, but also adds a sense of security, further adding to its appeal.¹³ As suggested by the economist Richard Thaler, simple nudges may be required to increase use and perhaps utility of telemedicine or e-consults.¹⁴ At this stage, it is the active choice of the referral or triaging provider to consider telemedicine as an option. To facilitate deviation from the established routine, we plan to revise the consult requests by using a drop-down menu option that brings up e-consult, telemedicine, or clinic visit as alternatives and requires an active choice rather than defaulting to conventional face-to-face visits.

Despite an overall successful launch of the specialty telemedicine clinic, several conceptual questions require additional in-depth assessments. While video visits indeed include the literal face time that characterizes normal clinic visits, does this translate into the “face value” that may contribute to treatment success? If detailed information about physical findings is needed, remote encounters require a third person at the distant site to complete this step, which may not only be a logistic burden, but also could influence the perceived utility and affect outcomes.

Previously published studies have demonstrated the effectiveness of video-based interactions and allow providers to address these points to some degree. Remote encounters have established roles in mental healthcare that is less dependent on physical findings.¹⁵ Distance monitoring of devices or biomarkers, such as blood sugar levels or blood pressure, are becoming routine and often are combined with corrective interventions.^16-18

Recently completed trials showed satisfaction did not differ from conventional clinic encounters when telemedicine encounters were used to manage chronic headaches or provide postoperative follow-up after urologic surgery.^19,20 For gastroenterology, telemedicine outreach after hospitalizations not only improved care, but also lowered rates of testing after discharge.²¹ In patients with inflammatory bowel disease, a group that was not targeted during this initial phase, proactive and close follow-up with remote technology can decrease the need for hospitalization.²²

These data are consistent with encouraging feedback received. Nonetheless, it is important to assess whether this approach is superior to established and cheaper alternatives, most notably simple telephone interactions. Video-linkage obviously allows nonverbal elements of communication, which play an important role in patient preference and satisfaction, treatment implementation, and impact.^7,8,23-25 Providers described patients as more focused and engaged compared with telephone interactions and valued the ability to incorporate body language in their assessment.²⁶

Telemedicine clinics offered by specialty providers may not improve access as defined by wait times only, which would require adding more clinical time and personnel. However, it can lower barriers to care imposed by long distances between rural areas and facilities with specialized expertise. Even if a remote encounter concludes with the recommendation to visit the clinic for more detailed testing or treatment, explaining the need for such steps and involving the patient in the decision-making process may affect adherence.

Conclusion

Although the experiences of the team at George E. Wahlen VA Medical Center support the use of telemedicine in specialty clinics, the next phase of the project needs to address the utility of this approach and define the perceived value and potential problems of telemedicine. Obtaining this insight will require complex data sets with feedback from patients and referring and consulting providers. As trade-offs will likely vary between different diseases or symptoms, such studies will provide a better definition of clinical scenarios best suited for remote encounters. In addition, they may provide approximate values for distance or efforts that may make the cost of a direct clinic visit worth it, thereby defining boundary-condition.

Access to specialized services has been a consistently complex problem for many integrated health care systems, including the Veterans Health Administration (VHA). About two-thirds of veterans experience significant barriers when trying to obtain medical care.¹ While these problems partly mirror difficulties that nonveterans face as well, there is a unique obligation toward those who put life and health at risk during their military service.²

To better meet demands, the VHA expanded personnel and clinic infrastructure with more providers and a network of community-based outpatient clinics (CBOC) that created more openings for clinic visits.³ Yet regional variability remains a significant problem for primary and even more so for specialty medical services.

Recent data show that more than one-fifth of all veterans live in areas with low population density and shortages of health care providers.⁴ The data point at a special problem in this context because these veterans often face long travel times to centers offering specialty services. The introduction of electronic consults functions as an alternative venue to obtain expert input but amounts to only 2% of total consult volume.⁵ A more interactive approach with face-to-face teleconferencing, case discussions, and special training led by expert clinicians has further improved access in such underserved areas and played a key role in the success of the VHA hepatitis C treatment initiative.⁶

Despite its clearly proven role and success, these e-consults come with some conceptual shortcomings. A key caveat is the lack of direct patient involvement. Obtaining information from the source rather than relying on symptoms documented by a third person can be essential in approaching medical problems. Experts may be able to tease out the often essential details of a history when making a diagnosis. A direct contact adds an additional, perhaps less tangible, component to the interaction that relies on verbal and nonverbal components of personal interactions and plays an important role in treatment success. Prior studies strongly link credibility of and trust in a provider as well as the related treatment success to such aspects of communication.^7,8

Gastroenterology Telemedicine Services

The George E. Wahlen VA Medical Center in Salt Lake City, Utah, draws from a large catchment area that extends from the southern border of Utah to the neighboring states of Idaho, Wyoming, Nevada, and Montana. Large stretches of this territory are remote with population densities well below 5 persons per square mile. The authors therefore devised a specialty outreach program relying on telemedicine for patients with gastrointestinal and liver diseases and present the initial experience with the implementation of this program.

Phase 1: Finding the Champions

Prior studies clearly emphasized that most successful telemedicine clinics relied on key persons (“champions”) promoting the idea and carrying the additional logistic and time issues required to start and maintain the new program^.9,10 Thus we created a small team that defined and refined goals, identified target groups, and worked out the logistics. Based on prior experiences, we focused initially on veterans with more chronic and likely functional disorders, such as diarrhea, constipation, dyspepsia, or nausea. The team also planned to accept patients with chronic liver disorders or abnormal test results that required further clarification. By consensus, the group excluded acute problems and bleeding as well as disorders with pain as primary manifestations. The underlying assumption was that a direct physical examination was less critical in most of these cases.

Phase 2: Outreach

Clinic managers and medical directors of the affiliated CBOC were informed of the planned telemedicine clinic. Also, we identified local champions who could function as point persons and assist in the organization of visits. One member of the team personally visited key sites to discuss needs and opportunities with CBOC personnel during a routine staff meeting. The goal was to introduce the program, the key personnel, to explain criteria for appropriate candidates that may benefit from telemedicine consults, and to agree on a referral pathway. Finally, we emphasized that the consultant would always defer to the referring provider or patient and honor their requests.

Phase 3: Identifying Appropriate Patients

The team planned for and has since used 4 different pathways to identify possible candidates for telemedicine visits. The consult triaging process with telemedicine is an option that is brought up with patients if their travel to the facility exceeds 100 miles. Similarly, the team reviews procedural requests to optimize diagnostic yields and limit patient burden. For example, if endoscopic testing is requested to address chronic abdominal pain or other concerns that had already prompted a similar request with negative results, then the team will ask for feedback and recommend a telemedicine consultation prior to performing the procedure. Telemedicine also is offered for follow-up encounters to veterans seen in the facility for clinical or procedural evaluations if they live ≥ 40 miles away. The 2 other pathways are requests from referring providers or patients that specifically ask for telemedicine visits.

Phase 4: Implementation

Since rolling out the program in November 2016, video visits have been used for more than 150 clinic encounters. Within the first 12 months, 124 patients were seen at least once using telemedicine links. Of 144 visits, 54 (38%) were follow-up visits; the rest constituted initial consultations. Focusing on initial encounters only, veterans specifically asked for a telemedicine visit in 16 cases (17.8%). One-third of these referrals was specifically marked as a telemedicine visit by the primary care provider. In the remaining cases, the triaging personnel brought up the possibility of a telemedicine interaction and requested feedback from the referring provider.

Veterans resided in many different areas within and outside of the facility’s immediate referral area (Figure). 

Beyond obtaining contextual data and information about the specific clinical manifestations, the rationale for these encounters was a detailed discussion of the problem and treatment options available. Ablative therapy in Barrett esophagus best exemplifies the potential relevance of such an encounter: Although conceptually appealing to decrease cancer risk, the approach requires a significant commitment typically involving repeated sessions of radiofrequency ablation followed by intense endoscopic surveillance. With travel distances of several hundred miles in these cases, these encounters provide relevant information to patients and the opportunity to make informed decisions without the burden and cost of a long trip.

A shift in telemedicine encounters will likely occur that will increasingly rely on access from home computers or handheld devices. However, the initial phase of this program relied on connections through a CBOC. Coordination between 2 sites adds a level of complexity to ensure availability of space and videoconferencing equipment. To limit the logistic burden and improve cost-effectiveness, the authors did not expect or request the presence of the primary or another independent provider. Instead, the team communicated with a locally designated point person who coordinated the remote encounters and assisted in implementing some of the suggested next steps. Prior site visits and communications with referring providers had established channels of communication to define concerns or highlight findings. The same channels also allowed the team to direct its attention to specific aspects of the physical examination to support or rule out a presumptive diagnosis.

If additional testing was suggested, Telemedicine Services generally ordered the appropriate assessments unless veterans requested relying on local resources better known to personnel at the remote site. The most common diagnostic steps recommended were laboratory tests (n = 21; 14.6%), endoscopic procedures (n = 18; 12.5%), and radiologic studies (n = 17; 11.8%) (Table 2).

Discussion

The initial implementation of a specialty telemedicine clinic taught us several lessons that will not only guide this program expansion, but also may be relevant for others introducing telemedicine into their specialty clinics. At first glance, videoconferencing with patients resembles more conventional clinic encounters. However, it adds another angle as many steps from scheduling a visit to implementing recommendations rely on different members at the remote site. Thus, the success of such a program depends on establishing a true partnership with the teams at the various satellite sites. It also requires ongoing feedback from all team members and fine-tuning to effectively integrate it into the routine operations of both sites.

Feedback about the program has been very positive with comments often asking for an expansion beyond gastroenterology. Concerns largely were limited to scheduling problems that may become less relevant if the new telehealth initiative moves forward and enables health care providers to directly connect with computers or handheld devices at the patient’s home. Prior studies demonstrated that most individuals have access to such technology and accept it as a viable or even attractive option for medical encounters.^11,12

For some, remaining in the comfort of their own home is not only more convenient, but also adds a sense of security, further adding to its appeal.¹³ As suggested by the economist Richard Thaler, simple nudges may be required to increase use and perhaps utility of telemedicine or e-consults.¹⁴ At this stage, it is the active choice of the referral or triaging provider to consider telemedicine as an option. To facilitate deviation from the established routine, we plan to revise the consult requests by using a drop-down menu option that brings up e-consult, telemedicine, or clinic visit as alternatives and requires an active choice rather than defaulting to conventional face-to-face visits.

Despite an overall successful launch of the specialty telemedicine clinic, several conceptual questions require additional in-depth assessments. While video visits indeed include the literal face time that characterizes normal clinic visits, does this translate into the “face value” that may contribute to treatment success? If detailed information about physical findings is needed, remote encounters require a third person at the distant site to complete this step, which may not only be a logistic burden, but also could influence the perceived utility and affect outcomes.

Previously published studies have demonstrated the effectiveness of video-based interactions and allow providers to address these points to some degree. Remote encounters have established roles in mental healthcare that is less dependent on physical findings.¹⁵ Distance monitoring of devices or biomarkers, such as blood sugar levels or blood pressure, are becoming routine and often are combined with corrective interventions.^16-18

Recently completed trials showed satisfaction did not differ from conventional clinic encounters when telemedicine encounters were used to manage chronic headaches or provide postoperative follow-up after urologic surgery.^19,20 For gastroenterology, telemedicine outreach after hospitalizations not only improved care, but also lowered rates of testing after discharge.²¹ In patients with inflammatory bowel disease, a group that was not targeted during this initial phase, proactive and close follow-up with remote technology can decrease the need for hospitalization.²²

These data are consistent with encouraging feedback received. Nonetheless, it is important to assess whether this approach is superior to established and cheaper alternatives, most notably simple telephone interactions. Video-linkage obviously allows nonverbal elements of communication, which play an important role in patient preference and satisfaction, treatment implementation, and impact.^7,8,23-25 Providers described patients as more focused and engaged compared with telephone interactions and valued the ability to incorporate body language in their assessment.²⁶

Telemedicine clinics offered by specialty providers may not improve access as defined by wait times only, which would require adding more clinical time and personnel. However, it can lower barriers to care imposed by long distances between rural areas and facilities with specialized expertise. Even if a remote encounter concludes with the recommendation to visit the clinic for more detailed testing or treatment, explaining the need for such steps and involving the patient in the decision-making process may affect adherence.

Conclusion

Although the experiences of the team at George E. Wahlen VA Medical Center support the use of telemedicine in specialty clinics, the next phase of the project needs to address the utility of this approach and define the perceived value and potential problems of telemedicine. Obtaining this insight will require complex data sets with feedback from patients and referring and consulting providers. As trade-offs will likely vary between different diseases or symptoms, such studies will provide a better definition of clinical scenarios best suited for remote encounters. In addition, they may provide approximate values for distance or efforts that may make the cost of a direct clinic visit worth it, thereby defining boundary-condition.

Access to specialized services has been a consistently complex problem for many integrated health care systems, including the Veterans Health Administration (VHA). About two-thirds of veterans experience significant barriers when trying to obtain medical care.¹ While these problems partly mirror difficulties that nonveterans face as well, there is a unique obligation toward those who put life and health at risk during their military service.²

To better meet demands, the VHA expanded personnel and clinic infrastructure with more providers and a network of community-based outpatient clinics (CBOC) that created more openings for clinic visits.³ Yet regional variability remains a significant problem for primary and even more so for specialty medical services.

Recent data show that more than one-fifth of all veterans live in areas with low population density and shortages of health care providers.⁴ The data point at a special problem in this context because these veterans often face long travel times to centers offering specialty services. The introduction of electronic consults functions as an alternative venue to obtain expert input but amounts to only 2% of total consult volume.⁵ A more interactive approach with face-to-face teleconferencing, case discussions, and special training led by expert clinicians has further improved access in such underserved areas and played a key role in the success of the VHA hepatitis C treatment initiative.⁶

Despite its clearly proven role and success, these e-consults come with some conceptual shortcomings. A key caveat is the lack of direct patient involvement. Obtaining information from the source rather than relying on symptoms documented by a third person can be essential in approaching medical problems. Experts may be able to tease out the often essential details of a history when making a diagnosis. A direct contact adds an additional, perhaps less tangible, component to the interaction that relies on verbal and nonverbal components of personal interactions and plays an important role in treatment success. Prior studies strongly link credibility of and trust in a provider as well as the related treatment success to such aspects of communication.^7,8

Gastroenterology Telemedicine Services

The George E. Wahlen VA Medical Center in Salt Lake City, Utah, draws from a large catchment area that extends from the southern border of Utah to the neighboring states of Idaho, Wyoming, Nevada, and Montana. Large stretches of this territory are remote with population densities well below 5 persons per square mile. The authors therefore devised a specialty outreach program relying on telemedicine for patients with gastrointestinal and liver diseases and present the initial experience with the implementation of this program.

Phase 1: Finding the Champions

Prior studies clearly emphasized that most successful telemedicine clinics relied on key persons (“champions”) promoting the idea and carrying the additional logistic and time issues required to start and maintain the new program^.9,10 Thus we created a small team that defined and refined goals, identified target groups, and worked out the logistics. Based on prior experiences, we focused initially on veterans with more chronic and likely functional disorders, such as diarrhea, constipation, dyspepsia, or nausea. The team also planned to accept patients with chronic liver disorders or abnormal test results that required further clarification. By consensus, the group excluded acute problems and bleeding as well as disorders with pain as primary manifestations. The underlying assumption was that a direct physical examination was less critical in most of these cases.

Phase 2: Outreach

Clinic managers and medical directors of the affiliated CBOC were informed of the planned telemedicine clinic. Also, we identified local champions who could function as point persons and assist in the organization of visits. One member of the team personally visited key sites to discuss needs and opportunities with CBOC personnel during a routine staff meeting. The goal was to introduce the program, the key personnel, to explain criteria for appropriate candidates that may benefit from telemedicine consults, and to agree on a referral pathway. Finally, we emphasized that the consultant would always defer to the referring provider or patient and honor their requests.

Phase 3: Identifying Appropriate Patients

The team planned for and has since used 4 different pathways to identify possible candidates for telemedicine visits. The consult triaging process with telemedicine is an option that is brought up with patients if their travel to the facility exceeds 100 miles. Similarly, the team reviews procedural requests to optimize diagnostic yields and limit patient burden. For example, if endoscopic testing is requested to address chronic abdominal pain or other concerns that had already prompted a similar request with negative results, then the team will ask for feedback and recommend a telemedicine consultation prior to performing the procedure. Telemedicine also is offered for follow-up encounters to veterans seen in the facility for clinical or procedural evaluations if they live ≥ 40 miles away. The 2 other pathways are requests from referring providers or patients that specifically ask for telemedicine visits.

Phase 4: Implementation

Since rolling out the program in November 2016, video visits have been used for more than 150 clinic encounters. Within the first 12 months, 124 patients were seen at least once using telemedicine links. Of 144 visits, 54 (38%) were follow-up visits; the rest constituted initial consultations. Focusing on initial encounters only, veterans specifically asked for a telemedicine visit in 16 cases (17.8%). One-third of these referrals was specifically marked as a telemedicine visit by the primary care provider. In the remaining cases, the triaging personnel brought up the possibility of a telemedicine interaction and requested feedback from the referring provider.

Veterans resided in many different areas within and outside of the facility’s immediate referral area (Figure). 

Beyond obtaining contextual data and information about the specific clinical manifestations, the rationale for these encounters was a detailed discussion of the problem and treatment options available. Ablative therapy in Barrett esophagus best exemplifies the potential relevance of such an encounter: Although conceptually appealing to decrease cancer risk, the approach requires a significant commitment typically involving repeated sessions of radiofrequency ablation followed by intense endoscopic surveillance. With travel distances of several hundred miles in these cases, these encounters provide relevant information to patients and the opportunity to make informed decisions without the burden and cost of a long trip.

A shift in telemedicine encounters will likely occur that will increasingly rely on access from home computers or handheld devices. However, the initial phase of this program relied on connections through a CBOC. Coordination between 2 sites adds a level of complexity to ensure availability of space and videoconferencing equipment. To limit the logistic burden and improve cost-effectiveness, the authors did not expect or request the presence of the primary or another independent provider. Instead, the team communicated with a locally designated point person who coordinated the remote encounters and assisted in implementing some of the suggested next steps. Prior site visits and communications with referring providers had established channels of communication to define concerns or highlight findings. The same channels also allowed the team to direct its attention to specific aspects of the physical examination to support or rule out a presumptive diagnosis.

If additional testing was suggested, Telemedicine Services generally ordered the appropriate assessments unless veterans requested relying on local resources better known to personnel at the remote site. The most common diagnostic steps recommended were laboratory tests (n = 21; 14.6%), endoscopic procedures (n = 18; 12.5%), and radiologic studies (n = 17; 11.8%) (Table 2).

Discussion

The initial implementation of a specialty telemedicine clinic taught us several lessons that will not only guide this program expansion, but also may be relevant for others introducing telemedicine into their specialty clinics. At first glance, videoconferencing with patients resembles more conventional clinic encounters. However, it adds another angle as many steps from scheduling a visit to implementing recommendations rely on different members at the remote site. Thus, the success of such a program depends on establishing a true partnership with the teams at the various satellite sites. It also requires ongoing feedback from all team members and fine-tuning to effectively integrate it into the routine operations of both sites.

Feedback about the program has been very positive with comments often asking for an expansion beyond gastroenterology. Concerns largely were limited to scheduling problems that may become less relevant if the new telehealth initiative moves forward and enables health care providers to directly connect with computers or handheld devices at the patient’s home. Prior studies demonstrated that most individuals have access to such technology and accept it as a viable or even attractive option for medical encounters.^11,12

For some, remaining in the comfort of their own home is not only more convenient, but also adds a sense of security, further adding to its appeal.¹³ As suggested by the economist Richard Thaler, simple nudges may be required to increase use and perhaps utility of telemedicine or e-consults.¹⁴ At this stage, it is the active choice of the referral or triaging provider to consider telemedicine as an option. To facilitate deviation from the established routine, we plan to revise the consult requests by using a drop-down menu option that brings up e-consult, telemedicine, or clinic visit as alternatives and requires an active choice rather than defaulting to conventional face-to-face visits.

Despite an overall successful launch of the specialty telemedicine clinic, several conceptual questions require additional in-depth assessments. While video visits indeed include the literal face time that characterizes normal clinic visits, does this translate into the “face value” that may contribute to treatment success? If detailed information about physical findings is needed, remote encounters require a third person at the distant site to complete this step, which may not only be a logistic burden, but also could influence the perceived utility and affect outcomes.

Previously published studies have demonstrated the effectiveness of video-based interactions and allow providers to address these points to some degree. Remote encounters have established roles in mental healthcare that is less dependent on physical findings.¹⁵ Distance monitoring of devices or biomarkers, such as blood sugar levels or blood pressure, are becoming routine and often are combined with corrective interventions.^16-18

Recently completed trials showed satisfaction did not differ from conventional clinic encounters when telemedicine encounters were used to manage chronic headaches or provide postoperative follow-up after urologic surgery.^19,20 For gastroenterology, telemedicine outreach after hospitalizations not only improved care, but also lowered rates of testing after discharge.²¹ In patients with inflammatory bowel disease, a group that was not targeted during this initial phase, proactive and close follow-up with remote technology can decrease the need for hospitalization.²²

These data are consistent with encouraging feedback received. Nonetheless, it is important to assess whether this approach is superior to established and cheaper alternatives, most notably simple telephone interactions. Video-linkage obviously allows nonverbal elements of communication, which play an important role in patient preference and satisfaction, treatment implementation, and impact.^7,8,23-25 Providers described patients as more focused and engaged compared with telephone interactions and valued the ability to incorporate body language in their assessment.²⁶

Telemedicine clinics offered by specialty providers may not improve access as defined by wait times only, which would require adding more clinical time and personnel. However, it can lower barriers to care imposed by long distances between rural areas and facilities with specialized expertise. Even if a remote encounter concludes with the recommendation to visit the clinic for more detailed testing or treatment, explaining the need for such steps and involving the patient in the decision-making process may affect adherence.

Conclusion

Although the experiences of the team at George E. Wahlen VA Medical Center support the use of telemedicine in specialty clinics, the next phase of the project needs to address the utility of this approach and define the perceived value and potential problems of telemedicine. Obtaining this insight will require complex data sets with feedback from patients and referring and consulting providers. As trade-offs will likely vary between different diseases or symptoms, such studies will provide a better definition of clinical scenarios best suited for remote encounters. In addition, they may provide approximate values for distance or efforts that may make the cost of a direct clinic visit worth it, thereby defining boundary-condition.

Since the approval of infliximab in 2005 as the first biologic agent to treat ulcerative colitis, more UC patients are having multiple operations to manage their disease and their surgical outcomes tend to be worse, according to a study published in Annals of Surgery.

“Encouragingly, early randomized controlled trials demonstrated that infliximab may reduce the short-term need for surgery,” wrote Jonathan Abelson, MD, of the department of surgery, Cornell University, New York, and his coauthors. “However, even after the development and approval of several other biologic agents to treat UC, 30%-66% of patients treated with biologic agents still ultimately require surgical intervention.”

The study reviewed records of 7,070 patients with UC in a New York State Department of Health database who had colorectal surgery in two comparative time periods: 3,803 from 1995 to 2005, before biologics were available, and 3,267 from 2006 to 2013, after infliximab was approved. Dr. Abelson and coauthors said this is the first study to look at long-term surgical outcomes in a large group of patients with UC over an extended time period. Previous studies have reported conflicting results of how biologic agents for UC can impact surgical outcomes. The researchers set out to explore two hypotheses: whether staged procedures increased after 2005 and whether UC patients had worse outcomes over the past decade. The study results validated both hypotheses. Up until 2005, the proportion of patients who underwent at least three procedures after the index hospitalization was 9%; after 2006, that proportion was 14% (P less than .01).

SOURCE: Abelson JS et al. Ann Surg. 2018:268;311-7.

Since the approval of infliximab in 2005 as the first biologic agent to treat ulcerative colitis, more UC patients are having multiple operations to manage their disease and their surgical outcomes tend to be worse, according to a study published in Annals of Surgery.

“Encouragingly, early randomized controlled trials demonstrated that infliximab may reduce the short-term need for surgery,” wrote Jonathan Abelson, MD, of the department of surgery, Cornell University, New York, and his coauthors. “However, even after the development and approval of several other biologic agents to treat UC, 30%-66% of patients treated with biologic agents still ultimately require surgical intervention.”

The study reviewed records of 7,070 patients with UC in a New York State Department of Health database who had colorectal surgery in two comparative time periods: 3,803 from 1995 to 2005, before biologics were available, and 3,267 from 2006 to 2013, after infliximab was approved. Dr. Abelson and coauthors said this is the first study to look at long-term surgical outcomes in a large group of patients with UC over an extended time period. Previous studies have reported conflicting results of how biologic agents for UC can impact surgical outcomes. The researchers set out to explore two hypotheses: whether staged procedures increased after 2005 and whether UC patients had worse outcomes over the past decade. The study results validated both hypotheses. Up until 2005, the proportion of patients who underwent at least three procedures after the index hospitalization was 9%; after 2006, that proportion was 14% (P less than .01).

SOURCE: Abelson JS et al. Ann Surg. 2018:268;311-7.

Since the approval of infliximab in 2005 as the first biologic agent to treat ulcerative colitis, more UC patients are having multiple operations to manage their disease and their surgical outcomes tend to be worse, according to a study published in Annals of Surgery.

“Encouragingly, early randomized controlled trials demonstrated that infliximab may reduce the short-term need for surgery,” wrote Jonathan Abelson, MD, of the department of surgery, Cornell University, New York, and his coauthors. “However, even after the development and approval of several other biologic agents to treat UC, 30%-66% of patients treated with biologic agents still ultimately require surgical intervention.”

The study reviewed records of 7,070 patients with UC in a New York State Department of Health database who had colorectal surgery in two comparative time periods: 3,803 from 1995 to 2005, before biologics were available, and 3,267 from 2006 to 2013, after infliximab was approved. Dr. Abelson and coauthors said this is the first study to look at long-term surgical outcomes in a large group of patients with UC over an extended time period. Previous studies have reported conflicting results of how biologic agents for UC can impact surgical outcomes. The researchers set out to explore two hypotheses: whether staged procedures increased after 2005 and whether UC patients had worse outcomes over the past decade. The study results validated both hypotheses. Up until 2005, the proportion of patients who underwent at least three procedures after the index hospitalization was 9%; after 2006, that proportion was 14% (P less than .01).

SOURCE: Abelson JS et al. Ann Surg. 2018:268;311-7.

Case Presentation. A 64-year-old US Army veteran with a history of colorectal cancer, melanoma, and fibrinolytic presented with dyspnea to VA Boston Healthcare System (VABHS). Seven years prior to the current presentation, at the time of her diagnosis of colorectal cancer, the patient was found to be HIV negative but to have a positive purified protein derivative (PPD) test. She was treated with isoniazid (INH) therapy for 9 months. Sputum cultures collected prior to initiation of therapy grew Mycobacterium avium complex (MAC) in 1 of 3 samples, with these results reported several months after initiation of therapy. She was a never smoker with no known travel or exposure. At the time of the current presentation, her medications included bupropion, levothyroxine, capsaicin, cyclobenzaprine, ibuprofen, and acetaminophen.

►Lakshmana Swamy, MD, Chief Medical Resident, VABHS and Boston Medical Center. Dr. Monach, this patient is on a variety of pain medications and has a diagnosis of fibromyalgia. This diagnosis often frustrates doctors and patients alike. Can you tell us about fibromyalgia from the rheumatologist’s perspective and what you think of her current treatment regimen?

►Paul A. Monach, MD, PhD, Chief, Section of Rheumatology, VABHS and Associate Professor of Medicine, Boston University School of Medicine. Fibromyalgia is a syndrome of chronic widespread pain without known pathology in the musculoskeletal system. It is thought to be caused by chronic dysfunction of pain-processing pathways in the central nervous system (CNS). It is often accompanied by other somatic symptoms such as chronic fatigue, irritable bowel syndrome, and bladder pain. It is a common condition, affecting up to 5% of otherwise healthy women. It is particularly common in persons with chronic nonrestorative sleep or posttraumatic stress disorder from a wide range of causes. However, it also is more common in persons with autoimmune inflammatory diseases, such as lupus, Sjögren syndrome, or rheumatoid arthritis. Concern for one of these diseases is the main reason to consider referring a patient for evaluation by a rheumatologist. Often rheumatologists participate in the management of fibromyalgia. A patient should be given appropriate expectations by the referring physician.

Effectiveness of treatment varies widely among patients. Nonpharmacologic approaches such as aerobic exercise, cognitive behavioral therapy, and tai chi have support from clinical trials, and yoga and aquatherapy also are widely used.^1,2 The classes of drugs used are the same as for neuropathic pain: tricyclics, including cyclobenzaprine; serotonin and norepinephrine reuptake inhibitors (SNRIs); and gabapentinoids. In contrast, nonsteroidal anti-inflammatory drugs and opioids are ineffective unless there is a superimposed mechanical or inflammatory cause in the periphery. The key point is that continuation of any treatment should be based entirely on the patient’s own assessment of benefit.

►Dr. Swamy. Seven years later, the patient returned to her primary care provider, reporting increased dyspnea on exertion as well as significant fatigue. She was referred to the pulmonary department and had repeat computed tomography (CT) scans of the chest, which indicated persistent right middle lobe (RML) bronchiectasis. She then underwent bronchoscopy with a subsequent bronchoalveolar lavage (BAL) culture growing MAC. Dr. Fine, please interpret the baseline and follow-up CT scans and help us understand the significance of the MAC on sputum and BAL cultures.

►Alan Fine, MD, Section of Pulmonary and Critical Care, VABHS and Professor of Medicine, Boston University School of Medicine. Prior to this presentation, the patient had a pleural-based area of fibrosis with possible associated RML bronchiectasis. This appears to be a postinflammatory process without classic features of malignant or metastatic disease. She then had a sputum, which grew MAC in only 1 of 3 samples and in liquid media only. Importantly, the sputum was not smear positive. All of this suggests a low organism burden. One possibility is that this could reflect colonization with MAC; it is not uncommon for patients with underlying chronic changes in their lung to grow MAC, and it is often difficult to tell whether it is indicative of active disease. Structural lung disease, such as bronchiectasis, predisposes a patient to MAC, but chronic MAC also may cause bronchiectasis. This chicken-and-egg scenario comes up frequently. She may have a MAC infection, but as she is HIV negative and asymptomatic, there is no urgent indication to treat, especially as the burden of therapy is not insignificant.

►Dr. Swamy. Do we need to worry about Mycobacterium tuberculosis (MTB)?

►Dr. Fine. Although she was previously PPD positive, she had already completed 1 year of isoniazid (INH) therapy, making active MTB less likely. From an infection control standpoint, it is important to distinguish MAC from MTB. The former is not contagious, and there is no need for airborne isolation.

►Dr. Swamy. Dr. Fine, where does MAC come from? Does it commonly cause disease?

►Dr. Fine. In the environment, MAC is nearly ubiquitous , especially in water and soil. In one study, 20% of showerheads were positive for MAC; when patients are infected, we may suggest changing/bleaching the showerhead, but there are no definitive recommendations.³ Because MAC is so common in the environment, it is unlikely that measures to target MAC colonization will be clinically meaningful. On the other hand, the incidence of nontuberculous mycobacterial infections is increasing across the US, and it may be a common and frequently underdiagnosed cause of chronic cough, especially in postmenopausal women.

►Dr. Swamy. Four years prior to the current presentation, the patient developed a cough after an upper respiratory tract infection that persisted for more than 2 weeks. Given her history, she underwent a repeat chest CT, which noted a slight increase in nodularity and ground-glass opacity restricted to the RML. She also reported dyspnea on exertion and was referred to the pulmonary medicine department. By the time she arrived, her dyspnea had largely resolved, but she reported persistent fatigue without other systemic symptoms, such as fevers or chills. Dr. Fine, does MAC explain this patient’s dyspnea?

►Dr. Fine. As her pulmonary symptoms resolved in a short period of time with only azithromycin, it is very unlikely that her symptoms were related to her prior disease. The MAC infection is not likely to cause dyspnea on exertion and fatigue and should be worked up more broadly before attributing it to MAC. In view of this, it would not be unreasonable to follow her clinically and see her again in 6 to 8 weeks. In this context, we also should consider the untoward impact of repeated radiation exposure derived from multiple CT scans. When a patient has an abnormality on CT scan, it often leads to further scans even if the symptoms do not match the previous findings, as in this case.

►Dr. Swamy. Given her ongoing fatigue and systemic symptoms (morning stiffness of the shoulders, legs, and thighs, and leg cramps), she was referred to the rheumatology department where the physical examination revealed muscle tenderness in her proximal arms and legs with normal strength, tender points at the elbows and medial side of the bilateral knees, significant tenderness of lower legs, and no synovitis.

Dr. Monach, can you walk us through your approach to this patient? Are we seeing manifestations of fibromyalgia? What diagnoses concerns you and how would you proceed?

►Dr. Monach. The history and exam are most helpful in raising or reducing suspicion for an underlying inflammatory disease. Areas of tenderness described in her case are typical of fibromyalgia, although it can be difficult to interpret symptoms in the hip girdle and shoulder girdle because objective findings are often absent on exam in patients with inflammatory arthritis or bursitis. Similarly, tenderness at sites of tendon insertion (enthuses) without objective abnormalities is common in different forms of spondyloarthritis, so tenderness at the elbow, knee, lateral hip, and low back can be difficult to interpret. What this patient is lacking is prominent subjective or objective findings in the joints most commonly affected in rheumatoid arthritis and lupus: wrists, hands, ankles, and feet.

►Dr. Swamy. Initial laboratory data include an erythrocyte sedimentation rate of 79 with a normal C-reactive protein. A tentative diagnosis of polymyalgia rheumatic is made with consideration of a trial treatment of prednisone.

Dr. Monach, this patient has an indolent infection and is about to be given glucocorticoids. Could you describe the situations in which you feel that glucocorticoids cause a relative immunosuppression?

►Dr. Monach. Glucocorticoids are considered safe in a patient whose infection is not intrinsically dangerous or who has started appropriate antibiotics for that infection. Although all toxicities of glucocorticoids are dose dependent, the long-standing assertion that doses below 10 mg to 15 mg do not increase risk of infection is contradicted by data published in the past 10 to 15 years, with the caveat that these patients were on long-term treatment.

►Dr. Swamy. The patient was started on prednisone 15 mg per day for 15 days. She returned to the clinic after 1 week of prednisone troutment and noted “significant improvement in fatigue, morning stiffness of shoulders, thighs, leg, back is better, leg cramps resolved, shooting pain in many joints resolved.” Further laboratory results were notable for a negative rheumatoid factor, negative antinuclear antibody, and a cyclic citrullinated peptide of 60. A presumptive diagnosis of rheumatoid arthritis (RA) was made and plaquenil 200 mg twice daily was started.

Dr. Monach, can you explain why RA comes up now on serology but was not considered initially? Why does this presentation fit RA, and was her response to treatment typical? How does this fit in with her previous diagnosis of fibromyalgia? Was that just an atypical, indolent presentation of RA?

►Dr. Monach. Though her presentation is atypical for RA, in elderly patients, RA can present with symptoms resembling polymyalgia rheumatica. The question is whether she had RA all along (in which case “elderly onset” would not apply) or had fibromyalgia and developed RA more recently. The response to empiric glucocorticoid therapy is helpful, since fibromyalgia should not improve with prednisone even in a patient with RA unless treatment of RA would allow better sleep and ability to exercise. Rheumatoid arthritis typically responds very well to prednisone in the 5-mg to 15-mg range.

►Dr. Swamy. Given the new diagnosis of an inflammatory arthritis requiring immunosuppression, bronchoscopy with BAL is performed to evaluate for the presence of MAC. These cultures were positive for MAC.

Dr. Fine, does the positive BAL culture indicate an active MAC infection?

►Dr. Fine. Yes, based on these updated data, the patient has an active MAC infection. Active infection is defined as symptoms or imaging consistent with the diagnosis, supporting microbiology data (either 2 sputum or 1 BAL sample growing MAC) and the exclusion of other causes. Previously, this patient grew MAC in just one expectorated sputum; this did not meet the microbiologic criteria. Now sputum has grown in the BAL sample; along with the CT imaging, this is enough to diagnosis active MAC infection.

Treatment for MAC must consider the details of each case. First, this is not an emergency; treatment decisions should be made with the rheumatologist to consider the planned immunosuppression. For example, we must consider potential drug interactions. A specific point should be made of the use of tumor necrosis factor (TNF)-α inhibition, which data indicate can reactivate TB and may inhibit mechanisms that restrain mycobacterial disease. Serious cases of MAC infection have been reported in the literature in the setting of TNF-α inhibition.^5,6 Despite these concerns, there is not a contraindication to using these therapies from the perspective of the active MAC disease. All of these decisions will impact the need to commit the patient to MAC therapy.

►Dr. Swamy. Dr. Fine, what do you consider prior to initiating MAC therapy?

► Dr. Fine. The decision to pursue MAC therapy should not be taken lightly. Therapy often entails prolonged multidrug regimens, usually spanning more than a year, with frequent adverse effects. Outside of very specific cases, such as TNF-β inhibition, MAC is rarely a life-threatening disease, so the benefit may be limited. Treatment for MAC is certainly unlikely to be fruitful without a diligent and motivated patient able to handle the high and prolonged pill burden. Of note, it is also important to keep this patient up-to-date with influenza and pneumonia vaccination given her structural lung disease.

►Dr. Swamy. The decision is made to treat MAC with azithromycin, rifampin, and ethambutol. The disease is noted to be nonfibrocavitary. The patient underwent monthly liver function test monitoring and visual acuity testing, which were unremarkable. Dr. Fine, can you describe the phenotypes of nontuberculous mycobacterial (NTM) disease?

►Dr. Fine. There are 3 main phenotypes of NTM.³ First, we see the elderly man with preexisting lung disease—usually chronic obstructive pulmonary disease—with fibrocavitary and/or reticulonodular appearance. Second, we see the slim, elderly woman often without any preexisting lung disease presenting with focal bronchiectasis and nodular lesions in right middle lobe and lingula—the Lady Windermere syndrome. This eponym is derived from Oscar Wilde’s play “Lady Windermere’s Fan, a Play About a Good Woman,” and was first associated with this disease in 1992.⁷ At the time, it was thought that the voluntary suppression of cough led to poorly draining lung regions, vulnerable to engraftment by atypical mycobacteria. Infection with atypical mycobacteria are associated with this population; however, it is no longer thought to be due to the voluntary suppression of cough.^7,8 Third, we do occasionally see atypical presentations, such as focal masses and solitary nodules.

►Dr. Swamy. At 1-year follow-up she successfully completed MAC therapy and noted ongoing control of rheumatoid symptoms.

Case Presentation. A 64-year-old US Army veteran with a history of colorectal cancer, melanoma, and fibrinolytic presented with dyspnea to VA Boston Healthcare System (VABHS). Seven years prior to the current presentation, at the time of her diagnosis of colorectal cancer, the patient was found to be HIV negative but to have a positive purified protein derivative (PPD) test. She was treated with isoniazid (INH) therapy for 9 months. Sputum cultures collected prior to initiation of therapy grew Mycobacterium avium complex (MAC) in 1 of 3 samples, with these results reported several months after initiation of therapy. She was a never smoker with no known travel or exposure. At the time of the current presentation, her medications included bupropion, levothyroxine, capsaicin, cyclobenzaprine, ibuprofen, and acetaminophen.

►Lakshmana Swamy, MD, Chief Medical Resident, VABHS and Boston Medical Center. Dr. Monach, this patient is on a variety of pain medications and has a diagnosis of fibromyalgia. This diagnosis often frustrates doctors and patients alike. Can you tell us about fibromyalgia from the rheumatologist’s perspective and what you think of her current treatment regimen?

►Paul A. Monach, MD, PhD, Chief, Section of Rheumatology, VABHS and Associate Professor of Medicine, Boston University School of Medicine. Fibromyalgia is a syndrome of chronic widespread pain without known pathology in the musculoskeletal system. It is thought to be caused by chronic dysfunction of pain-processing pathways in the central nervous system (CNS). It is often accompanied by other somatic symptoms such as chronic fatigue, irritable bowel syndrome, and bladder pain. It is a common condition, affecting up to 5% of otherwise healthy women. It is particularly common in persons with chronic nonrestorative sleep or posttraumatic stress disorder from a wide range of causes. However, it also is more common in persons with autoimmune inflammatory diseases, such as lupus, Sjögren syndrome, or rheumatoid arthritis. Concern for one of these diseases is the main reason to consider referring a patient for evaluation by a rheumatologist. Often rheumatologists participate in the management of fibromyalgia. A patient should be given appropriate expectations by the referring physician.

Effectiveness of treatment varies widely among patients. Nonpharmacologic approaches such as aerobic exercise, cognitive behavioral therapy, and tai chi have support from clinical trials, and yoga and aquatherapy also are widely used.^1,2 The classes of drugs used are the same as for neuropathic pain: tricyclics, including cyclobenzaprine; serotonin and norepinephrine reuptake inhibitors (SNRIs); and gabapentinoids. In contrast, nonsteroidal anti-inflammatory drugs and opioids are ineffective unless there is a superimposed mechanical or inflammatory cause in the periphery. The key point is that continuation of any treatment should be based entirely on the patient’s own assessment of benefit.

►Dr. Swamy. Seven years later, the patient returned to her primary care provider, reporting increased dyspnea on exertion as well as significant fatigue. She was referred to the pulmonary department and had repeat computed tomography (CT) scans of the chest, which indicated persistent right middle lobe (RML) bronchiectasis. She then underwent bronchoscopy with a subsequent bronchoalveolar lavage (BAL) culture growing MAC. Dr. Fine, please interpret the baseline and follow-up CT scans and help us understand the significance of the MAC on sputum and BAL cultures.

►Alan Fine, MD, Section of Pulmonary and Critical Care, VABHS and Professor of Medicine, Boston University School of Medicine. Prior to this presentation, the patient had a pleural-based area of fibrosis with possible associated RML bronchiectasis. This appears to be a postinflammatory process without classic features of malignant or metastatic disease. She then had a sputum, which grew MAC in only 1 of 3 samples and in liquid media only. Importantly, the sputum was not smear positive. All of this suggests a low organism burden. One possibility is that this could reflect colonization with MAC; it is not uncommon for patients with underlying chronic changes in their lung to grow MAC, and it is often difficult to tell whether it is indicative of active disease. Structural lung disease, such as bronchiectasis, predisposes a patient to MAC, but chronic MAC also may cause bronchiectasis. This chicken-and-egg scenario comes up frequently. She may have a MAC infection, but as she is HIV negative and asymptomatic, there is no urgent indication to treat, especially as the burden of therapy is not insignificant.

►Dr. Swamy. Do we need to worry about Mycobacterium tuberculosis (MTB)?

►Dr. Fine. Although she was previously PPD positive, she had already completed 1 year of isoniazid (INH) therapy, making active MTB less likely. From an infection control standpoint, it is important to distinguish MAC from MTB. The former is not contagious, and there is no need for airborne isolation.

►Dr. Swamy. Dr. Fine, where does MAC come from? Does it commonly cause disease?

►Dr. Fine. In the environment, MAC is nearly ubiquitous , especially in water and soil. In one study, 20% of showerheads were positive for MAC; when patients are infected, we may suggest changing/bleaching the showerhead, but there are no definitive recommendations.³ Because MAC is so common in the environment, it is unlikely that measures to target MAC colonization will be clinically meaningful. On the other hand, the incidence of nontuberculous mycobacterial infections is increasing across the US, and it may be a common and frequently underdiagnosed cause of chronic cough, especially in postmenopausal women.

►Dr. Swamy. Four years prior to the current presentation, the patient developed a cough after an upper respiratory tract infection that persisted for more than 2 weeks. Given her history, she underwent a repeat chest CT, which noted a slight increase in nodularity and ground-glass opacity restricted to the RML. She also reported dyspnea on exertion and was referred to the pulmonary medicine department. By the time she arrived, her dyspnea had largely resolved, but she reported persistent fatigue without other systemic symptoms, such as fevers or chills. Dr. Fine, does MAC explain this patient’s dyspnea?

►Dr. Fine. As her pulmonary symptoms resolved in a short period of time with only azithromycin, it is very unlikely that her symptoms were related to her prior disease. The MAC infection is not likely to cause dyspnea on exertion and fatigue and should be worked up more broadly before attributing it to MAC. In view of this, it would not be unreasonable to follow her clinically and see her again in 6 to 8 weeks. In this context, we also should consider the untoward impact of repeated radiation exposure derived from multiple CT scans. When a patient has an abnormality on CT scan, it often leads to further scans even if the symptoms do not match the previous findings, as in this case.

►Dr. Swamy. Given her ongoing fatigue and systemic symptoms (morning stiffness of the shoulders, legs, and thighs, and leg cramps), she was referred to the rheumatology department where the physical examination revealed muscle tenderness in her proximal arms and legs with normal strength, tender points at the elbows and medial side of the bilateral knees, significant tenderness of lower legs, and no synovitis.

Dr. Monach, can you walk us through your approach to this patient? Are we seeing manifestations of fibromyalgia? What diagnoses concerns you and how would you proceed?

►Dr. Monach. The history and exam are most helpful in raising or reducing suspicion for an underlying inflammatory disease. Areas of tenderness described in her case are typical of fibromyalgia, although it can be difficult to interpret symptoms in the hip girdle and shoulder girdle because objective findings are often absent on exam in patients with inflammatory arthritis or bursitis. Similarly, tenderness at sites of tendon insertion (enthuses) without objective abnormalities is common in different forms of spondyloarthritis, so tenderness at the elbow, knee, lateral hip, and low back can be difficult to interpret. What this patient is lacking is prominent subjective or objective findings in the joints most commonly affected in rheumatoid arthritis and lupus: wrists, hands, ankles, and feet.

►Dr. Swamy. Initial laboratory data include an erythrocyte sedimentation rate of 79 with a normal C-reactive protein. A tentative diagnosis of polymyalgia rheumatic is made with consideration of a trial treatment of prednisone.

Dr. Monach, this patient has an indolent infection and is about to be given glucocorticoids. Could you describe the situations in which you feel that glucocorticoids cause a relative immunosuppression?

►Dr. Monach. Glucocorticoids are considered safe in a patient whose infection is not intrinsically dangerous or who has started appropriate antibiotics for that infection. Although all toxicities of glucocorticoids are dose dependent, the long-standing assertion that doses below 10 mg to 15 mg do not increase risk of infection is contradicted by data published in the past 10 to 15 years, with the caveat that these patients were on long-term treatment.

►Dr. Swamy. The patient was started on prednisone 15 mg per day for 15 days. She returned to the clinic after 1 week of prednisone troutment and noted “significant improvement in fatigue, morning stiffness of shoulders, thighs, leg, back is better, leg cramps resolved, shooting pain in many joints resolved.” Further laboratory results were notable for a negative rheumatoid factor, negative antinuclear antibody, and a cyclic citrullinated peptide of 60. A presumptive diagnosis of rheumatoid arthritis (RA) was made and plaquenil 200 mg twice daily was started.

Dr. Monach, can you explain why RA comes up now on serology but was not considered initially? Why does this presentation fit RA, and was her response to treatment typical? How does this fit in with her previous diagnosis of fibromyalgia? Was that just an atypical, indolent presentation of RA?

►Dr. Monach. Though her presentation is atypical for RA, in elderly patients, RA can present with symptoms resembling polymyalgia rheumatica. The question is whether she had RA all along (in which case “elderly onset” would not apply) or had fibromyalgia and developed RA more recently. The response to empiric glucocorticoid therapy is helpful, since fibromyalgia should not improve with prednisone even in a patient with RA unless treatment of RA would allow better sleep and ability to exercise. Rheumatoid arthritis typically responds very well to prednisone in the 5-mg to 15-mg range.

►Dr. Swamy. Given the new diagnosis of an inflammatory arthritis requiring immunosuppression, bronchoscopy with BAL is performed to evaluate for the presence of MAC. These cultures were positive for MAC.

Dr. Fine, does the positive BAL culture indicate an active MAC infection?

►Dr. Fine. Yes, based on these updated data, the patient has an active MAC infection. Active infection is defined as symptoms or imaging consistent with the diagnosis, supporting microbiology data (either 2 sputum or 1 BAL sample growing MAC) and the exclusion of other causes. Previously, this patient grew MAC in just one expectorated sputum; this did not meet the microbiologic criteria. Now sputum has grown in the BAL sample; along with the CT imaging, this is enough to diagnosis active MAC infection.

Treatment for MAC must consider the details of each case. First, this is not an emergency; treatment decisions should be made with the rheumatologist to consider the planned immunosuppression. For example, we must consider potential drug interactions. A specific point should be made of the use of tumor necrosis factor (TNF)-α inhibition, which data indicate can reactivate TB and may inhibit mechanisms that restrain mycobacterial disease. Serious cases of MAC infection have been reported in the literature in the setting of TNF-α inhibition.^5,6 Despite these concerns, there is not a contraindication to using these therapies from the perspective of the active MAC disease. All of these decisions will impact the need to commit the patient to MAC therapy.

►Dr. Swamy. Dr. Fine, what do you consider prior to initiating MAC therapy?

► Dr. Fine. The decision to pursue MAC therapy should not be taken lightly. Therapy often entails prolonged multidrug regimens, usually spanning more than a year, with frequent adverse effects. Outside of very specific cases, such as TNF-β inhibition, MAC is rarely a life-threatening disease, so the benefit may be limited. Treatment for MAC is certainly unlikely to be fruitful without a diligent and motivated patient able to handle the high and prolonged pill burden. Of note, it is also important to keep this patient up-to-date with influenza and pneumonia vaccination given her structural lung disease.

►Dr. Swamy. The decision is made to treat MAC with azithromycin, rifampin, and ethambutol. The disease is noted to be nonfibrocavitary. The patient underwent monthly liver function test monitoring and visual acuity testing, which were unremarkable. Dr. Fine, can you describe the phenotypes of nontuberculous mycobacterial (NTM) disease?

►Dr. Fine. There are 3 main phenotypes of NTM.³ First, we see the elderly man with preexisting lung disease—usually chronic obstructive pulmonary disease—with fibrocavitary and/or reticulonodular appearance. Second, we see the slim, elderly woman often without any preexisting lung disease presenting with focal bronchiectasis and nodular lesions in right middle lobe and lingula—the Lady Windermere syndrome. This eponym is derived from Oscar Wilde’s play “Lady Windermere’s Fan, a Play About a Good Woman,” and was first associated with this disease in 1992.⁷ At the time, it was thought that the voluntary suppression of cough led to poorly draining lung regions, vulnerable to engraftment by atypical mycobacteria. Infection with atypical mycobacteria are associated with this population; however, it is no longer thought to be due to the voluntary suppression of cough.^7,8 Third, we do occasionally see atypical presentations, such as focal masses and solitary nodules.

►Dr. Swamy. At 1-year follow-up she successfully completed MAC therapy and noted ongoing control of rheumatoid symptoms.

Case Presentation. A 64-year-old US Army veteran with a history of colorectal cancer, melanoma, and fibrinolytic presented with dyspnea to VA Boston Healthcare System (VABHS). Seven years prior to the current presentation, at the time of her diagnosis of colorectal cancer, the patient was found to be HIV negative but to have a positive purified protein derivative (PPD) test. She was treated with isoniazid (INH) therapy for 9 months. Sputum cultures collected prior to initiation of therapy grew Mycobacterium avium complex (MAC) in 1 of 3 samples, with these results reported several months after initiation of therapy. She was a never smoker with no known travel or exposure. At the time of the current presentation, her medications included bupropion, levothyroxine, capsaicin, cyclobenzaprine, ibuprofen, and acetaminophen.

►Lakshmana Swamy, MD, Chief Medical Resident, VABHS and Boston Medical Center. Dr. Monach, this patient is on a variety of pain medications and has a diagnosis of fibromyalgia. This diagnosis often frustrates doctors and patients alike. Can you tell us about fibromyalgia from the rheumatologist’s perspective and what you think of her current treatment regimen?

►Paul A. Monach, MD, PhD, Chief, Section of Rheumatology, VABHS and Associate Professor of Medicine, Boston University School of Medicine. Fibromyalgia is a syndrome of chronic widespread pain without known pathology in the musculoskeletal system. It is thought to be caused by chronic dysfunction of pain-processing pathways in the central nervous system (CNS). It is often accompanied by other somatic symptoms such as chronic fatigue, irritable bowel syndrome, and bladder pain. It is a common condition, affecting up to 5% of otherwise healthy women. It is particularly common in persons with chronic nonrestorative sleep or posttraumatic stress disorder from a wide range of causes. However, it also is more common in persons with autoimmune inflammatory diseases, such as lupus, Sjögren syndrome, or rheumatoid arthritis. Concern for one of these diseases is the main reason to consider referring a patient for evaluation by a rheumatologist. Often rheumatologists participate in the management of fibromyalgia. A patient should be given appropriate expectations by the referring physician.

Effectiveness of treatment varies widely among patients. Nonpharmacologic approaches such as aerobic exercise, cognitive behavioral therapy, and tai chi have support from clinical trials, and yoga and aquatherapy also are widely used.^1,2 The classes of drugs used are the same as for neuropathic pain: tricyclics, including cyclobenzaprine; serotonin and norepinephrine reuptake inhibitors (SNRIs); and gabapentinoids. In contrast, nonsteroidal anti-inflammatory drugs and opioids are ineffective unless there is a superimposed mechanical or inflammatory cause in the periphery. The key point is that continuation of any treatment should be based entirely on the patient’s own assessment of benefit.

►Dr. Swamy. Seven years later, the patient returned to her primary care provider, reporting increased dyspnea on exertion as well as significant fatigue. She was referred to the pulmonary department and had repeat computed tomography (CT) scans of the chest, which indicated persistent right middle lobe (RML) bronchiectasis. She then underwent bronchoscopy with a subsequent bronchoalveolar lavage (BAL) culture growing MAC. Dr. Fine, please interpret the baseline and follow-up CT scans and help us understand the significance of the MAC on sputum and BAL cultures.

►Alan Fine, MD, Section of Pulmonary and Critical Care, VABHS and Professor of Medicine, Boston University School of Medicine. Prior to this presentation, the patient had a pleural-based area of fibrosis with possible associated RML bronchiectasis. This appears to be a postinflammatory process without classic features of malignant or metastatic disease. She then had a sputum, which grew MAC in only 1 of 3 samples and in liquid media only. Importantly, the sputum was not smear positive. All of this suggests a low organism burden. One possibility is that this could reflect colonization with MAC; it is not uncommon for patients with underlying chronic changes in their lung to grow MAC, and it is often difficult to tell whether it is indicative of active disease. Structural lung disease, such as bronchiectasis, predisposes a patient to MAC, but chronic MAC also may cause bronchiectasis. This chicken-and-egg scenario comes up frequently. She may have a MAC infection, but as she is HIV negative and asymptomatic, there is no urgent indication to treat, especially as the burden of therapy is not insignificant.

►Dr. Swamy. Do we need to worry about Mycobacterium tuberculosis (MTB)?

►Dr. Fine. Although she was previously PPD positive, she had already completed 1 year of isoniazid (INH) therapy, making active MTB less likely. From an infection control standpoint, it is important to distinguish MAC from MTB. The former is not contagious, and there is no need for airborne isolation.

►Dr. Swamy. Dr. Fine, where does MAC come from? Does it commonly cause disease?

►Dr. Fine. In the environment, MAC is nearly ubiquitous , especially in water and soil. In one study, 20% of showerheads were positive for MAC; when patients are infected, we may suggest changing/bleaching the showerhead, but there are no definitive recommendations.³ Because MAC is so common in the environment, it is unlikely that measures to target MAC colonization will be clinically meaningful. On the other hand, the incidence of nontuberculous mycobacterial infections is increasing across the US, and it may be a common and frequently underdiagnosed cause of chronic cough, especially in postmenopausal women.

►Dr. Swamy. Four years prior to the current presentation, the patient developed a cough after an upper respiratory tract infection that persisted for more than 2 weeks. Given her history, she underwent a repeat chest CT, which noted a slight increase in nodularity and ground-glass opacity restricted to the RML. She also reported dyspnea on exertion and was referred to the pulmonary medicine department. By the time she arrived, her dyspnea had largely resolved, but she reported persistent fatigue without other systemic symptoms, such as fevers or chills. Dr. Fine, does MAC explain this patient’s dyspnea?

►Dr. Fine. As her pulmonary symptoms resolved in a short period of time with only azithromycin, it is very unlikely that her symptoms were related to her prior disease. The MAC infection is not likely to cause dyspnea on exertion and fatigue and should be worked up more broadly before attributing it to MAC. In view of this, it would not be unreasonable to follow her clinically and see her again in 6 to 8 weeks. In this context, we also should consider the untoward impact of repeated radiation exposure derived from multiple CT scans. When a patient has an abnormality on CT scan, it often leads to further scans even if the symptoms do not match the previous findings, as in this case.

►Dr. Swamy. Given her ongoing fatigue and systemic symptoms (morning stiffness of the shoulders, legs, and thighs, and leg cramps), she was referred to the rheumatology department where the physical examination revealed muscle tenderness in her proximal arms and legs with normal strength, tender points at the elbows and medial side of the bilateral knees, significant tenderness of lower legs, and no synovitis.

Dr. Monach, can you walk us through your approach to this patient? Are we seeing manifestations of fibromyalgia? What diagnoses concerns you and how would you proceed?

►Dr. Monach. The history and exam are most helpful in raising or reducing suspicion for an underlying inflammatory disease. Areas of tenderness described in her case are typical of fibromyalgia, although it can be difficult to interpret symptoms in the hip girdle and shoulder girdle because objective findings are often absent on exam in patients with inflammatory arthritis or bursitis. Similarly, tenderness at sites of tendon insertion (enthuses) without objective abnormalities is common in different forms of spondyloarthritis, so tenderness at the elbow, knee, lateral hip, and low back can be difficult to interpret. What this patient is lacking is prominent subjective or objective findings in the joints most commonly affected in rheumatoid arthritis and lupus: wrists, hands, ankles, and feet.

►Dr. Swamy. Initial laboratory data include an erythrocyte sedimentation rate of 79 with a normal C-reactive protein. A tentative diagnosis of polymyalgia rheumatic is made with consideration of a trial treatment of prednisone.

Dr. Monach, this patient has an indolent infection and is about to be given glucocorticoids. Could you describe the situations in which you feel that glucocorticoids cause a relative immunosuppression?

►Dr. Monach. Glucocorticoids are considered safe in a patient whose infection is not intrinsically dangerous or who has started appropriate antibiotics for that infection. Although all toxicities of glucocorticoids are dose dependent, the long-standing assertion that doses below 10 mg to 15 mg do not increase risk of infection is contradicted by data published in the past 10 to 15 years, with the caveat that these patients were on long-term treatment.

►Dr. Swamy. The patient was started on prednisone 15 mg per day for 15 days. She returned to the clinic after 1 week of prednisone troutment and noted “significant improvement in fatigue, morning stiffness of shoulders, thighs, leg, back is better, leg cramps resolved, shooting pain in many joints resolved.” Further laboratory results were notable for a negative rheumatoid factor, negative antinuclear antibody, and a cyclic citrullinated peptide of 60. A presumptive diagnosis of rheumatoid arthritis (RA) was made and plaquenil 200 mg twice daily was started.

Dr. Monach, can you explain why RA comes up now on serology but was not considered initially? Why does this presentation fit RA, and was her response to treatment typical? How does this fit in with her previous diagnosis of fibromyalgia? Was that just an atypical, indolent presentation of RA?

►Dr. Monach. Though her presentation is atypical for RA, in elderly patients, RA can present with symptoms resembling polymyalgia rheumatica. The question is whether she had RA all along (in which case “elderly onset” would not apply) or had fibromyalgia and developed RA more recently. The response to empiric glucocorticoid therapy is helpful, since fibromyalgia should not improve with prednisone even in a patient with RA unless treatment of RA would allow better sleep and ability to exercise. Rheumatoid arthritis typically responds very well to prednisone in the 5-mg to 15-mg range.

►Dr. Swamy. Given the new diagnosis of an inflammatory arthritis requiring immunosuppression, bronchoscopy with BAL is performed to evaluate for the presence of MAC. These cultures were positive for MAC.

Dr. Fine, does the positive BAL culture indicate an active MAC infection?

►Dr. Fine. Yes, based on these updated data, the patient has an active MAC infection. Active infection is defined as symptoms or imaging consistent with the diagnosis, supporting microbiology data (either 2 sputum or 1 BAL sample growing MAC) and the exclusion of other causes. Previously, this patient grew MAC in just one expectorated sputum; this did not meet the microbiologic criteria. Now sputum has grown in the BAL sample; along with the CT imaging, this is enough to diagnosis active MAC infection.

Treatment for MAC must consider the details of each case. First, this is not an emergency; treatment decisions should be made with the rheumatologist to consider the planned immunosuppression. For example, we must consider potential drug interactions. A specific point should be made of the use of tumor necrosis factor (TNF)-α inhibition, which data indicate can reactivate TB and may inhibit mechanisms that restrain mycobacterial disease. Serious cases of MAC infection have been reported in the literature in the setting of TNF-α inhibition.^5,6 Despite these concerns, there is not a contraindication to using these therapies from the perspective of the active MAC disease. All of these decisions will impact the need to commit the patient to MAC therapy.

►Dr. Swamy. Dr. Fine, what do you consider prior to initiating MAC therapy?

► Dr. Fine. The decision to pursue MAC therapy should not be taken lightly. Therapy often entails prolonged multidrug regimens, usually spanning more than a year, with frequent adverse effects. Outside of very specific cases, such as TNF-β inhibition, MAC is rarely a life-threatening disease, so the benefit may be limited. Treatment for MAC is certainly unlikely to be fruitful without a diligent and motivated patient able to handle the high and prolonged pill burden. Of note, it is also important to keep this patient up-to-date with influenza and pneumonia vaccination given her structural lung disease.

►Dr. Swamy. The decision is made to treat MAC with azithromycin, rifampin, and ethambutol. The disease is noted to be nonfibrocavitary. The patient underwent monthly liver function test monitoring and visual acuity testing, which were unremarkable. Dr. Fine, can you describe the phenotypes of nontuberculous mycobacterial (NTM) disease?

►Dr. Fine. There are 3 main phenotypes of NTM.³ First, we see the elderly man with preexisting lung disease—usually chronic obstructive pulmonary disease—with fibrocavitary and/or reticulonodular appearance. Second, we see the slim, elderly woman often without any preexisting lung disease presenting with focal bronchiectasis and nodular lesions in right middle lobe and lingula—the Lady Windermere syndrome. This eponym is derived from Oscar Wilde’s play “Lady Windermere’s Fan, a Play About a Good Woman,” and was first associated with this disease in 1992.⁷ At the time, it was thought that the voluntary suppression of cough led to poorly draining lung regions, vulnerable to engraftment by atypical mycobacteria. Infection with atypical mycobacteria are associated with this population; however, it is no longer thought to be due to the voluntary suppression of cough.^7,8 Third, we do occasionally see atypical presentations, such as focal masses and solitary nodules.

►Dr. Swamy. At 1-year follow-up she successfully completed MAC therapy and noted ongoing control of rheumatoid symptoms.

Orlando – Clinical N2 disease may be a negative predictor of pathological complete response (PCR) after neoadjuvant chemoradiotherapy for rectal cancer, an analysis of a large, multicenter database has suggested.

jacoblund/Thinkstock

In multivariate regression, pretreatment N2 stage was the only variable significantly associated with failure of achieving pathologic complete response, according to Ebram Salama, MD, of Sir Mortimer B. Davis Jewish General Hospital at McGill University, Montreal.

“We should be reconsidering putting these patients in watch-and-wait protocols,” Dr. Salama said in an oral abstract presentation at the American College of Surgeons Quality and Safety Conference.

The analysis included 369 elective cases of cT2-4 N0-2 rectal cancer that were treated with neoadjuvant chemoradiotherapy during 2016 from the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) proctectomy-specific database.

Of those cases, 53 (14.4%) achieved PCR, a proportion consistent with what has been reported previously in medical literature, Dr. Salama noted during his presentation.

The multivariate analysis revealed that pretreatment N2 stage was a negative predictor of PCR with an odds ratio of 0.18 (95% confidence interval, 0.04-0.82; P = .026), according to presented data.

By contrast, Dr. Salama said, there were no significant associations between response and other variables, including pretreatment N1 stage, pretreatment T stage, tumor location, gender, or body mass index.

Dr. Salama acknowledged limitations of this retrospective study, including a lack of data on other variables of interest, such as carcinoembryonic antigen, tumor size, imaging characteristics, molecular markers, and the time interval between chemoradiotherapy and surgery.

“We obviously need more data to evaluate other predictive factors in achieving a complete pathological response,” he said, adding that it’s also unclear whether the results of the present study could be generalized to institutions not participating in ACS NSQIP.

Dr. Salama presented the research on behalf of Nathalie Wong-Chong, MD, also of McGill University. He had no conflicts of interest to report for his presentation.

Orlando – Clinical N2 disease may be a negative predictor of pathological complete response (PCR) after neoadjuvant chemoradiotherapy for rectal cancer, an analysis of a large, multicenter database has suggested.

jacoblund/Thinkstock

In multivariate regression, pretreatment N2 stage was the only variable significantly associated with failure of achieving pathologic complete response, according to Ebram Salama, MD, of Sir Mortimer B. Davis Jewish General Hospital at McGill University, Montreal.

“We should be reconsidering putting these patients in watch-and-wait protocols,” Dr. Salama said in an oral abstract presentation at the American College of Surgeons Quality and Safety Conference.

The analysis included 369 elective cases of cT2-4 N0-2 rectal cancer that were treated with neoadjuvant chemoradiotherapy during 2016 from the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) proctectomy-specific database.

Of those cases, 53 (14.4%) achieved PCR, a proportion consistent with what has been reported previously in medical literature, Dr. Salama noted during his presentation.

The multivariate analysis revealed that pretreatment N2 stage was a negative predictor of PCR with an odds ratio of 0.18 (95% confidence interval, 0.04-0.82; P = .026), according to presented data.

By contrast, Dr. Salama said, there were no significant associations between response and other variables, including pretreatment N1 stage, pretreatment T stage, tumor location, gender, or body mass index.

Dr. Salama acknowledged limitations of this retrospective study, including a lack of data on other variables of interest, such as carcinoembryonic antigen, tumor size, imaging characteristics, molecular markers, and the time interval between chemoradiotherapy and surgery.

“We obviously need more data to evaluate other predictive factors in achieving a complete pathological response,” he said, adding that it’s also unclear whether the results of the present study could be generalized to institutions not participating in ACS NSQIP.

Dr. Salama presented the research on behalf of Nathalie Wong-Chong, MD, also of McGill University. He had no conflicts of interest to report for his presentation.

Orlando – Clinical N2 disease may be a negative predictor of pathological complete response (PCR) after neoadjuvant chemoradiotherapy for rectal cancer, an analysis of a large, multicenter database has suggested.

jacoblund/Thinkstock

In multivariate regression, pretreatment N2 stage was the only variable significantly associated with failure of achieving pathologic complete response, according to Ebram Salama, MD, of Sir Mortimer B. Davis Jewish General Hospital at McGill University, Montreal.

“We should be reconsidering putting these patients in watch-and-wait protocols,” Dr. Salama said in an oral abstract presentation at the American College of Surgeons Quality and Safety Conference.

The analysis included 369 elective cases of cT2-4 N0-2 rectal cancer that were treated with neoadjuvant chemoradiotherapy during 2016 from the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) proctectomy-specific database.

Of those cases, 53 (14.4%) achieved PCR, a proportion consistent with what has been reported previously in medical literature, Dr. Salama noted during his presentation.

The multivariate analysis revealed that pretreatment N2 stage was a negative predictor of PCR with an odds ratio of 0.18 (95% confidence interval, 0.04-0.82; P = .026), according to presented data.

By contrast, Dr. Salama said, there were no significant associations between response and other variables, including pretreatment N1 stage, pretreatment T stage, tumor location, gender, or body mass index.

Dr. Salama acknowledged limitations of this retrospective study, including a lack of data on other variables of interest, such as carcinoembryonic antigen, tumor size, imaging characteristics, molecular markers, and the time interval between chemoradiotherapy and surgery.

“We obviously need more data to evaluate other predictive factors in achieving a complete pathological response,” he said, adding that it’s also unclear whether the results of the present study could be generalized to institutions not participating in ACS NSQIP.

Dr. Salama presented the research on behalf of Nathalie Wong-Chong, MD, also of McGill University. He had no conflicts of interest to report for his presentation.

ORLANDO – Widespread implementation of enhanced recovery protocols at the state level resulted in a significant reduction in length of stay and complications in patients undergoing elective colectomy, an analysis shows.

The benefits were particularly pronounced in the subset of patients undergoing laparoscopic colectomy in the retrospective analysis, which included data for treated at four institutions in the Virginia Surgical Quality Collaborative Workgroup.

While the benefits of enhanced recovery after surgery (ERAS) are well known, most of the published data has come from single-institution experiences, according to investigator Traci L. Hedrick, MD, FACS, of the University of Virginia, Charlottesville.

At the American College of Surgeons Quality and Safety Conference, Dr. Hedrick presented risk-adjusted National Surgical Quality Improvement Program (NSQIP) data for 2,971 consecutive procedures during 2012-2016 at the University of Virginia, Winchester Medical Center, Carilion Clinic, and Inova Fairfax.

“Institutions came and went from the collaborative during this time period, so we focused on those institutions that maintained in the collaborative throughout the entire study protocol,” Dr. Hedrick said in her presentation.

Of the 2,971 procedures, about half (1,460) were performed after implementation of enhanced recovery protocols. Laparoscopic and open procedures were analyzed separately due to a substantial shift toward laparoscopic procedures, mainly during the 2012-2014 period, Dr. Hedrick said.

Among laparoscopic cases, there was a significant 1-day reduction in median length of stay, dropping from 4 days for pre–enhanced recovery protocol cases to 3 days for post–enhanced recovery protocol cases, Dr. Hedrick reported.

Observed morbidity also dropped significantly from 14.8% to 8.9% for the pre– and post–enhanced recovery cases, and the readmission rate fell significantly from 13% to 8.8%.

For open cases, there was a significant 1-day drop in median length of stay, from 4 to 3 days, but no significant differences in observed morbidity or readmission rates, according to Dr. Hedrick.

“As more of the patients were done laparoscopically, that really selected out the more complicated patients that were undergoing open procedures,” she said.

The protocols implemented by institutions in the Virginia collaborative group were generally uniform in important tenants of enhanced recovery, such as opioid minimization and avoidance of fasting, but specific elements were left up to each institution to improve buy-in, according to Dr. Hedrick.

“A lot of our protocols are very similar, particularly with regards to the order set,” Dr. Hedrick explained, “[but] I really am a firm believer in not being very strict about exactly what to use, because it’s so dependent on preference at the local level.”

The Virginia Surgical Quality Collaborative Workgroup is one of 20 regional ACS NSQIP collaboratives with the objective of improving surgical outcomes through multi-institutional collaboration, Dr. Hedrick said.

Dr. Hedrick and her coinvestigators had no relevant disclosures to report.

ORLANDO – Widespread implementation of enhanced recovery protocols at the state level resulted in a significant reduction in length of stay and complications in patients undergoing elective colectomy, an analysis shows.

The benefits were particularly pronounced in the subset of patients undergoing laparoscopic colectomy in the retrospective analysis, which included data for treated at four institutions in the Virginia Surgical Quality Collaborative Workgroup.

While the benefits of enhanced recovery after surgery (ERAS) are well known, most of the published data has come from single-institution experiences, according to investigator Traci L. Hedrick, MD, FACS, of the University of Virginia, Charlottesville.

At the American College of Surgeons Quality and Safety Conference, Dr. Hedrick presented risk-adjusted National Surgical Quality Improvement Program (NSQIP) data for 2,971 consecutive procedures during 2012-2016 at the University of Virginia, Winchester Medical Center, Carilion Clinic, and Inova Fairfax.

“Institutions came and went from the collaborative during this time period, so we focused on those institutions that maintained in the collaborative throughout the entire study protocol,” Dr. Hedrick said in her presentation.

Of the 2,971 procedures, about half (1,460) were performed after implementation of enhanced recovery protocols. Laparoscopic and open procedures were analyzed separately due to a substantial shift toward laparoscopic procedures, mainly during the 2012-2014 period, Dr. Hedrick said.

Among laparoscopic cases, there was a significant 1-day reduction in median length of stay, dropping from 4 days for pre–enhanced recovery protocol cases to 3 days for post–enhanced recovery protocol cases, Dr. Hedrick reported.

Observed morbidity also dropped significantly from 14.8% to 8.9% for the pre– and post–enhanced recovery cases, and the readmission rate fell significantly from 13% to 8.8%.

For open cases, there was a significant 1-day drop in median length of stay, from 4 to 3 days, but no significant differences in observed morbidity or readmission rates, according to Dr. Hedrick.

“As more of the patients were done laparoscopically, that really selected out the more complicated patients that were undergoing open procedures,” she said.

The protocols implemented by institutions in the Virginia collaborative group were generally uniform in important tenants of enhanced recovery, such as opioid minimization and avoidance of fasting, but specific elements were left up to each institution to improve buy-in, according to Dr. Hedrick.

“A lot of our protocols are very similar, particularly with regards to the order set,” Dr. Hedrick explained, “[but] I really am a firm believer in not being very strict about exactly what to use, because it’s so dependent on preference at the local level.”

The Virginia Surgical Quality Collaborative Workgroup is one of 20 regional ACS NSQIP collaboratives with the objective of improving surgical outcomes through multi-institutional collaboration, Dr. Hedrick said.

Dr. Hedrick and her coinvestigators had no relevant disclosures to report.

ORLANDO – Widespread implementation of enhanced recovery protocols at the state level resulted in a significant reduction in length of stay and complications in patients undergoing elective colectomy, an analysis shows.

The benefits were particularly pronounced in the subset of patients undergoing laparoscopic colectomy in the retrospective analysis, which included data for treated at four institutions in the Virginia Surgical Quality Collaborative Workgroup.

While the benefits of enhanced recovery after surgery (ERAS) are well known, most of the published data has come from single-institution experiences, according to investigator Traci L. Hedrick, MD, FACS, of the University of Virginia, Charlottesville.

At the American College of Surgeons Quality and Safety Conference, Dr. Hedrick presented risk-adjusted National Surgical Quality Improvement Program (NSQIP) data for 2,971 consecutive procedures during 2012-2016 at the University of Virginia, Winchester Medical Center, Carilion Clinic, and Inova Fairfax.

“Institutions came and went from the collaborative during this time period, so we focused on those institutions that maintained in the collaborative throughout the entire study protocol,” Dr. Hedrick said in her presentation.

Of the 2,971 procedures, about half (1,460) were performed after implementation of enhanced recovery protocols. Laparoscopic and open procedures were analyzed separately due to a substantial shift toward laparoscopic procedures, mainly during the 2012-2014 period, Dr. Hedrick said.

Among laparoscopic cases, there was a significant 1-day reduction in median length of stay, dropping from 4 days for pre–enhanced recovery protocol cases to 3 days for post–enhanced recovery protocol cases, Dr. Hedrick reported.

Observed morbidity also dropped significantly from 14.8% to 8.9% for the pre– and post–enhanced recovery cases, and the readmission rate fell significantly from 13% to 8.8%.

For open cases, there was a significant 1-day drop in median length of stay, from 4 to 3 days, but no significant differences in observed morbidity or readmission rates, according to Dr. Hedrick.

“As more of the patients were done laparoscopically, that really selected out the more complicated patients that were undergoing open procedures,” she said.

The protocols implemented by institutions in the Virginia collaborative group were generally uniform in important tenants of enhanced recovery, such as opioid minimization and avoidance of fasting, but specific elements were left up to each institution to improve buy-in, according to Dr. Hedrick.

“A lot of our protocols are very similar, particularly with regards to the order set,” Dr. Hedrick explained, “[but] I really am a firm believer in not being very strict about exactly what to use, because it’s so dependent on preference at the local level.”

The Virginia Surgical Quality Collaborative Workgroup is one of 20 regional ACS NSQIP collaboratives with the objective of improving surgical outcomes through multi-institutional collaboration, Dr. Hedrick said.

Dr. Hedrick and her coinvestigators had no relevant disclosures to report.